This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
-
Baylor College of Medicine- McNair Campus, Houston, Texas, United States, 77030
Ben Taub General Hospital, Houston, Texas, United States, 77030
CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, United States, 77030
Harris Health System- Smith Clinic, Houston, Texas, United States, 77054
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Baylor College of Medicine,
Martha P. Mims, MD, PhD, PRINCIPAL_INVESTIGATOR, Baylor College of Medicine
2025-11-15